Improving Quality of Life of Prostate Cancer Survivors With Androgen Deficiency

PHASE2CompletedINTERVENTIONAL

Enrollment

136

Participants

Timeline

Start Date

March 19, 2019

Primary Completion Date

May 16, 2025

Study Completion Date

July 16, 2025

Conditions

Prostate Cancer

Interventions

DRUG

Testosterone Cypionate 100 MG/ML

100 mg testosterone cypionate administered by intramuscular injection weekly for 12 weeks.

DRUG

Placebo

Placebo administered by intramuscular injection weekly for 12 weeks.

Trial Locations (3)

Johns Hopkins University, Baltimore

Brigham and Women's Hospital, Boston

Dana Farber Cancer Institute, Boston

All Listed Sponsors

collaborator

National Institute on Aging (NIA)

NIH

lead

Dana-Farber Cancer Institute

OTHER

NCT03716739 - Improving Quality of Life of Prostate Cancer Survivors With Androgen Deficiency | Biotech Hunter | Biotech Hunter